Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications
A Zaanan, K Meunier, F Sangar, JF Fléjou, F Praz - Cellular oncology, 2011 - Springer
Background Microsatellite instability (MSI) constitutes an important oncogenic molecular
pathway in colorectal cancer (CRC), representing approximately 15% of all colorectal …
pathway in colorectal cancer (CRC), representing approximately 15% of all colorectal …
Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach?
Although metastatic colorectal cancer is typically incurable, in a good percentage of patients
(20% to 50%) who have oligometastatic disease confined to a single organ--usually the liver …
(20% to 50%) who have oligometastatic disease confined to a single organ--usually the liver …
Colorectal cancer survival: an analysis of patients with metastatic disease synchronous and metachronous with the primary tumor
Background Whether metastatic colorectal cancer (mCRC) that presents synchronously with
the primary lesion behaves differently from mCRC that appears metachronously to the …
the primary lesion behaves differently from mCRC that appears metachronously to the …
Treatment options for advanced pancreatic cancer: a review
R Warsame, A Grothey - Expert review of anticancer therapy, 2012 - Taylor & Francis
Advanced pancreatic adenocarcinoma historically has a poor prognosis and the mortality
rate has remained unchanged for over a decade. Common treatment options for patients …
rate has remained unchanged for over a decade. Common treatment options for patients …
Current and future biomarkers in the treatment of colorectal cancer
Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. CRC develops as a
consequence of genomic instability, characterized by various genetic and epigenetic …
consequence of genomic instability, characterized by various genetic and epigenetic …
Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine
A Paulík, J Nekvindová, S Filip - Tumori Journal, 2020 - journals.sagepub.com
Colorectal cancer, one of the most frequent types of cancer worldwide, has a high mortality
rate. Irinotecan (CPT-11) has been approved for the treatment of advanced or metastatic …
rate. Irinotecan (CPT-11) has been approved for the treatment of advanced or metastatic …
ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
P Li, YJ Fang, F Li, QJ Ou, G Chen, G Ma - British journal of cancer, 2013 - nature.com
Background: Excision repair cross-complementation group 1 (ERCC1) expression status
has been identified as a candidate marker for predicting efficacy of oxaliplatin (OX) treatment …
has been identified as a candidate marker for predicting efficacy of oxaliplatin (OX) treatment …
[HTML][HTML] Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of …
CA Bellera, M Pulido, S Gourgou, L Collette… - European Journal of …, 2013 - Elsevier
INTRODUCTION: In randomised phase III cancer clinical trials, the most objectively defined
and only validated time-to-event endpoint is overall survival (OS). The appearance of new …
and only validated time-to-event endpoint is overall survival (OS). The appearance of new …
RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients
Background A major obstacle in treating colorectal cancer (CRC) is the acquired resistance
to chemotherapeutic agents. An important protein in the regulation of cancer cell death and …
to chemotherapeutic agents. An important protein in the regulation of cancer cell death and …
Elevated preoperative carcinoembryonic antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer
Y Peng, L Wang, J Gu - World journal of surgery, 2013 - Springer
Background The present study was designed to investigate the prognostic factors of stage
IIA (pT3N0M0) colon cancer. Methods We retrospectively reviewed consecutive patients with …
IIA (pT3N0M0) colon cancer. Methods We retrospectively reviewed consecutive patients with …